Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
JAZZ Catalyst Timeline
Dated clinical, regulatory and corporate events for Jazz Pharmaceuticals plc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Jazz Pharmaceuticals plc
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How JAZZ actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-11-12 | JZP3507 (formerly ONC206) | Pre-clinical data presentation | Pre-clinical |
Drug Pipeline Intelligence
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Xywav | |||
| Epidiolex/Epidyolex | |||
| Rylaze/Enrylaze | |||
| Zepzelca | |||
| Defitelio/defibrotide | |||
| Modeyso | |||
| Xyrem | |||
| Vyxeos | |||
| Ziihera |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Zanidatamab BiologicsMarketedNCT06282575 | Biliary Tract Cancer | Approved | RECRUITING | 286 | Apr 1, 2030 | ||||||
| Zanidatamab BiologicsMarketedNCT05152147 | Gastric Neoplasms | Approved | ACTIVE NOT_RECRUITING | 920 | Sep 30, 2027 | ||||||
| Zanidatamab BiologicsNCT06435429 | Metastatic HER2-positive Breast Cancer | Phase 3 | RECRUITING | 550 | Oct 18, 2030 | ||||||
| Zanidatamab BiologicsMarketedNCT06043427 | Gastroesophageal Adenocarcinoma | Approved | RECRUITING | 168 | Jul 31, 2027 | ||||||
| Zanidatamab BiologicsNCT06695845 | Breast Cancer | Phase 2 | RECRUITING | 200 | Dec 31, 2027 | ||||||
| Zanidatamab BiologicsNCT07102381 | HER2-positive Breast Cancer | Phase 2 | RECRUITING | 125 | May 2, 2030 | ||||||
| CBD-OS Small MoleculesNCT07723976 | Developmental and Epileptic Encephalopathy (DEE) | Phase 3 | RECRUITING | 120 | Sep 4, 2029 | ||||||
| CBD-OS Small MoleculesNCT07233239 | Focal Seizures | Phase 1 | RECRUITING | 100 | Nov 29, 2027 | ||||||
| JZP926 Small MoleculesNCT07723963 | Juvenile Myoclonic Epilepsy | NDA/BLA | RECRUITING | 260 | Aug 1, 2028 | ||||||
| JZP3507 Small MoleculesNCT07533942 | Meningioma | Phase 2 | RECRUITING | 30 | Oct 16, 2031 | ||||||
| ONC206 Small MoleculesNCT07282587 | Advanced Pheochromocytoma and Paraganglioma | Phase 2 | RECRUITING | 90 | Dec 15, 2028 | ||||||
| ONC206 Small MoleculesNCT04541082 | Central Nervous System Neoplasms | Phase 1 | ACTIVE NOT_RECRUITING | 35 | Sep 30, 2027 | ||||||
| JZP898 Small MoleculesNCT06108050 | Advanced Solid Tumor | Phase 1 | RECRUITING | 177 | May 31, 2028 | ||||||
| JZP815 Small MoleculesNCT05557045 | Advanced Cancer | Phase 1 | ACTIVE NOT_RECRUITING | 98 | Apr 1, 2028 | ||||||
| JZP269 Small MoleculesNCT07813663 | Undisclosed | Phase 1 | RECRUITING | 212 | Feb 27, 2027 | ||||||
| JZP047 Small MoleculesNCT07377539 | Undisclosed | Phase 1 | ACTIVE NOT_RECRUITING | 86 | Nov 30, 2026 | ||||||
| Lurbinectedin Small MoleculesMarketedNCT05091567 | Small-Cell Lung Cancer | Approved | ACTIVE NOT_RECRUITING | 676 | Feb 28, 2028 | ||||||
| Lurbinectedin Small MoleculesMarketedNCT07459634 | Extensive-stage Small-cell Lung Cancer | Approved | RECRUITING | 50 | Nov 4, 2029 | ||||||
| Lurbinectedin Small MoleculesNCT05734066 | Refractory Ewing Sarcoma | Phase 1/2 | RECRUITING | 60 | Apr 20, 2028 | ||||||
| Lurbinectedin Small MoleculesMarketedNCT05244239 | Extensive Stage Lung Small Cell Carcinoma | Approved | RECRUITING | 22 | Jul 28, 2027 | ||||||
| Vyxeos Small MoleculesMarketedNCT04217278 | Acute Myeloid Leukaemia | Approved | ACTIVE NOT_RECRUITING | 333 | May 1, 2026 | ||||||
| Xywav Small MoleculesMarketedNCT07625280 | Narcolepsy | Approved | RECRUITING | 120 | Jan 6, 2028 | ||||||
| Dordaviprone Small MoleculesMarketedNCT05580562 | H3 K27M | Approved | RECRUITING | 510 | Jun 1, 2028 | ||||||
| Vyxeos Small MoleculesMarketedNCT05260528 | Acute Myeloid Leukemia | Approved | RECRUITING | 248 | Feb 2, 2030 | ||||||
| CPX-351 Small MoleculesMarketedNCT03897127 | Acute Myeloid Leukemia | Approved | ACTIVE NOT_RECRUITING | 1,252 | Jun 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every JAZZ program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Ziihera BreakthroughPriority | HER2-positive advanced gastroesophageal adenocarcinoma | Phase 3 | 2026-10-23 | Median OS reached 27.0 months; 39.8% with Ziihera plus tislelizumab and chemotherapy alive at three years; Median OS was 22.9 months with Ziihera plus chemotherapy; Median OS was 19.6 months with trastuzumab plus chemotherapy; Ziihera plus chemotherapy reduced the risk of death by 24% (HR 0.76); Ziihera plus tislelizumab and chemotherapy reduced the risk of death by 35% (HR 0.65)Read More | Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| COZADD BRUCE CDirector | Option | 734 340,609 held | $136.18 | 11/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in JAZZ
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Sofinnova Investments, Inc. | 4.2 % (-8.7 %) | 97.79 M | 422.38 K | 15.61% ( 57.03 K) |
Ownership Trends
JAZZ Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How JAZZ ranks across every disease it competes in
JAZZ News
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
Jazz Pharmaceuticals announced its participation in several upcoming investor conferences. Management will hold fireside chats at the Jefferies London Global Healthcare Conference on November 17, and at the Piper Sandler and Citi's Global Healthcare Conferences on December 2. Audio webcasts of these events will be available on the company's website.
Read more →Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results
Jazz Pharmaceuticals reported third quarter 2026 revenues of $1.2 billion, a 10% increase year-over-year. The company raised its full-year revenue guidance and successfully launched Ziihera for HER2-positive gastroesophageal adenocarcinoma. Despite a GAAP net loss of $483.4 million, the acquisition of Actio strengthens its rare epilepsy portfolio.
Read more →Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026
Jazz Pharmaceuticals will present neuro-oncology data at the 2026 Society for Neuro-Oncology Annual Meeting in Philadelphia. The company highlighted the ongoing Phase 3 ACTION trial for Modeyso in diffuse glioma and a new Phase 2 study for JZP3507 in recurrent meningioma. These presentations detail progress on novel therapies targeting rare brain cancers.
Read more →Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026
Jazz Pharmaceuticals reported updated results from the Phase 3 HERIZON-GEA-01 trial at ESMO 2026. The trial showed that Ziihera combined with tislelizumab and chemotherapy achieved a median overall survival of 27 months, significantly better than trastuzumab. Nearly 40% of patients were alive at three years, indicating a durable survival benefit.
Read more →Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026
Jazz Pharmaceuticals has announced that it will report its third quarter financial results for 2026 on November 2, 2026. The report will be released after the close of U.S. financial markets, followed by a management-hosted webcast at 4:30 p.m. ET. Interested parties can register for the call in advance through the company's website.
Read more →Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences
Jazz Pharmaceuticals has successfully acquired Actio Biosciences for $820 million, enhancing its epilepsy pipeline with the addition of ABS-1230, a potential first-in-class therapy for KCNT1-related epilepsy. ABS-1230 has shown promising results in early trials, indicating significant seizure reductions in children. The acquisition aims to leverage Actio's precision biology expertise alongside Jazz's development capabilities.
Read more →Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA
Jazz Pharmaceuticals announced positive interim results from the Phase 3 HERIZON-GEA-01 trial, showing that Ziihera (zanidatamab-hrii) combined with chemotherapy significantly improves overall survival compared to trastuzumab plus chemotherapy for HER2+ gastroesophageal adenocarcinoma. The FDA recently approved Ziihera for first-line treatment, reinforcing its role as a new standard of care. The safety profile remains consistent with prior studies.
Read more →Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
Jazz Pharmaceuticals has announced the pricing of an upsized $1.1 billion offering of 1.875% exchangeable senior notes due 2032. The offering, which includes an option for additional notes, is expected to close on August 31, 2026. Concurrently, the company plans to repurchase approximately $225 million of its ordinary shares. The proceeds from the notes will be used for general corporate purposes.
Read more →Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
Jazz Pharmaceuticals has announced a private offering of $1.0 billion in exchangeable senior notes due 2032, aimed at qualified institutional buyers. The company will also repurchase up to $225 million of its ordinary shares concurrently with the offering. The proceeds from the offering are intended for general corporate purposes, although market conditions may affect the transaction.
Read more →U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
Jazz Pharmaceuticals announced FDA approval for Ziihera (zanidatamab-hrii) in combination with tislelizumab and chemotherapy for first-line treatment of advanced HER2-positive gastroesophageal adenocarcinoma. This approval establishes a new standard of care and is based on the HERIZON-GEA-01 trial results, which demonstrated significant improvements in overall and progression-free survival. The approval is significant for patients with limited treatment options.
Read more →Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
Jazz Pharmaceuticals has announced its acquisition of Actio Biosciences for $820 million upfront, with potential additional payments of up to $500 million. This acquisition includes ABS-1230, a novel therapy for KCNT1+ epilepsy, a rare condition with no current FDA-approved treatments. The deal is expected to close in the fourth quarter of 2026, pending customary conditions.
Read more →Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results
Jazz Pharmaceuticals reported strong financial results for the second quarter of 2026, achieving record revenues of $1.2 billion, a 16% increase year-over-year. The company raised its revenue guidance for the year, anticipating continued growth driven by its key products, including Xywav and Epidiolex. Additionally, Jazz is preparing to launch its new drug Ziihera pending FDA approval.
Read more →Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026
Jazz Pharmaceuticals has announced that it will report its second quarter financial results on August 3, 2026. The report will be released after the U.S. financial markets close, followed by a management-hosted webcast at 4:30 p.m. ET. Interested parties can register in advance for the call and access a replay via the company's website.
Read more →Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
Jazz Pharmaceuticals and AbCellera have announced a preclinical collaboration to develop T-cell engaging multispecific antibodies targeted at gastrointestinal cancers and other solid tumors. The agreement includes $56 million in upfront payments and up to $792 million in potential milestone payments. Jazz has the exclusive option to develop any therapeutic antibodies that result from the collaboration, further enhancing its oncology portfolio. This partnership is expected to leverage AbCellera's advanced antibody discovery capabilities to provide novel treatment options for difficult-to-treat cancers.
Read more →Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia
Jazz Pharmaceuticals presented 11 late-breaking data sets at SLEEP 2026 regarding Xywav for narcolepsy and idiopathic hypersomnia. The company highlighted real-world evidence showing improved patient outcomes and reduced cardiometabolic risk markers. Data indicated that mean time to reach a stable dose was approximately 42 days for both conditions. Additionally, initiation of Xywav was linked to decreases in systolic blood pressure and increases in HDL cholesterol.
Read more →Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
Jazz Pharmaceuticals announced that the Phase 3 LAGOON trial for Zepzelca (lurbinectedin) in second-line small cell lung cancer did not meet its primary endpoint of overall survival. Despite this, the safety profile remained consistent with previous data. The company plans to discuss the results with the FDA regarding post-marketing requirements for the second-line indication.
Read more →Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia
Jazz Pharmaceuticals will present 21 abstracts at SLEEP 2026, including 11 late-breaking presentations. The data focuses on Xywav treatment for narcolepsy and idiopathic hypersomnia. Key findings cover sleep inertia improvements and real-world dosing patterns. These results reflect ongoing clinical research into these rare sleep disorders.
Read more →Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Jazz Pharmaceuticals announced the publication of Phase 3 HERIZON-GEA-01 trial results in the New England Journal of Medicine, which showcase the efficacy and safety of Ziihera (zanidatamab-hrii). The trial demonstrated significant improvements in progression-free survival and overall survival outcomes in patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. Additional analyses revealed consistent benefits across different PD-L1 expression levels, reinforcing zanidatamab's clinical potential. The findings could reshape first-line treatment expectations for this cancer indication.
Read more →